Revelation Biosciences, Inc. (NASDAQ:REVB) Sees Significant Increase in Short Interest
by Tristan Rich · The Markets DailyRevelation Biosciences, Inc. (NASDAQ:REVB – Get Free Report) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totaling 29,141 shares, a growth of 183.7% from the November 30th total of 10,272 shares. Approximately 0.6% of the shares of the company are short sold. Based on an average daily trading volume, of 122,940 shares, the short-interest ratio is presently 0.2 days. Based on an average daily trading volume, of 122,940 shares, the short-interest ratio is presently 0.2 days. Approximately 0.6% of the shares of the company are short sold.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Revelation Biosciences stock. Sabby Management LLC lifted its position in shares of Revelation Biosciences, Inc. (NASDAQ:REVB – Free Report) by 214.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 207,051 shares of the company’s stock after acquiring an additional 141,262 shares during the quarter. Revelation Biosciences makes up about 0.3% of Sabby Management LLC’s investment portfolio, making the stock its 16th largest position. Sabby Management LLC owned approximately 1.34% of Revelation Biosciences worth $294,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 12.80% of the company’s stock.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (e)” rating on shares of Revelation Biosciences in a research report on Monday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.
Check Out Our Latest Stock Report on Revelation Biosciences
Revelation Biosciences Stock Down 1.0%
REVB traded down $0.01 during trading on Friday, hitting $0.86. The company’s stock had a trading volume of 32,411 shares, compared to its average volume of 256,308. The stock has a market capitalization of $5.10 million, a price-to-earnings ratio of -0.03 and a beta of -0.11. The firm’s 50 day moving average price is $1.03 and its two-hundred day moving average price is $1.86. Revelation Biosciences has a 12 month low of $0.83 and a 12 month high of $60.48.
Revelation Biosciences (NASDAQ:REVB – Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($1.77) EPS for the quarter, missing the consensus estimate of ($1.34) by ($0.43). On average, sell-side analysts forecast that Revelation Biosciences will post -49.33 earnings per share for the current year.
Revelation Biosciences Company Profile
Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.